Silicon Canals
No Result
View All Result
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Community partners
    • Amsterdam
    • Rise by Techleap.nl
    • EOR handbook by Atlas HXM
    • Guest Contributions
    • Business Wire
    • Sign up for our newsletter!
  • Global Jobs
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Contribute your content
    • Team
    • About us
  • Partner with us
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Community partners
    • Amsterdam
    • Rise by Techleap.nl
    • EOR handbook by Atlas HXM
    • Guest Contributions
    • Business Wire
    • Sign up for our newsletter!
  • Global Jobs
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Contribute your content
    • Team
    • About us
  • Partner with us
No Result
View All Result
Silicon Canals
No Result
View All Result

Dutch startup Protyon raises €600K to accelerate information-guided cancer treatment

Vishal Singh by Vishal Singh
May 11, 2023
in (Crowd)funding, News
Protyon

Protyon founders, Matthew Groves, Rositsa Jordanova and Hoang Nguyen | Image credit: Protyon

31
SHARES
LinkedInTwitterWhatsAppFacebook
Read this article in:

Netherlands-based Protyon, a company that guides clinicians towards personalised treatment and enhancing the quality of life for patients, announced on Thursday, May 11, that it has raised €600K in a pre-seed round of funding.

According to Protyon, it aims to help create a future in which every patient’s treatment includes a molecular visualisation of the illness, allowing medical professionals to select the “best” available therapy.

The raised capital will be used to expand Protyon’s technology and create a SaaS business model.

Investors in this round

The investment came from Dutch-based LUMO Labs and NOM, the regional development agency for the northern Netherlands.

- Partner content -
Atlas HXM EOR Employee of Record
How EOR is becoming a crucial tool in 2023
EOR gains importance as companies digitise and hire globally. Learn from industry leaders...Show More
EOR gains importance as companies digitise and hire globally. Learn from industry leaders using EOR with Atlas HXM.Show Less
Read more

Annemieke Wouterse, Investment Manager at NOM, says, “Unfortunately, everybody knows somebody with cancer. The 3D model and algorithm of Protyon help clinicians make the optimal decision for further medication in case of tumor mutation, enhancing patient quality of life and reducing healthcare costs.”

“This startup fits nicely in the strategy of NOM to invest in early-stage Life Sciences & Health propositions,” adds Wouterse.

Enhancing cancer therapy effectiveness

Founded in 2022 by Matthew Groves, Rositsa Jordanova, Hoang Nguyen and Josef Melcr, Protyon provides a service for analysis that looks at the effects of mutations in certain proteins targeted for therapy in lung cancer and uses this research to recommend treatment alternatives. 

The healthtech startup, a spin-out of Groningen University and its medical centre (UMCG), develops prediction software based on computational molecular modelling and artificial intelligence (AI).

Rositsa Jordanova, founding partner of Protyon, says, “We aim to empower the clinical decision-making process by providing an automated molecular modeling tool to assess the treatment efficacy on an individual level.”

“Our digital solution is guiding clinicians to choose the best available therapy and enhance the quality of life of lung cancer patients,” adds Jordanova.

According to Protyon, the behaviour of molecules is mimicked by computational molecular modelling, which is already employed in advanced medical techniques like medication creation for individualised treatment.

“Structural biology has been an immensely powerful tool in the generation of new drugs, but surprisingly this same information has not been used in a clinical setting,” says Matthew Groves, Protyon’s chief science officer. “However, the use of knowledge on how mutations impact drug targets on the molecular level has a huge potential impact on treatment choices.”

Protyon claims its use of molecular modelling for guided cancer therapy is distinct from earlier approaches that emphasised chemical research. “The unprecedented predictive power of our solution puts Protyon ahead of its competitors,” adds Groves.

Andy Lürling, LUMO Labs Founding Partner, says, “This technology has already proven to be very effective and complementary to other tools available to clinicians, and it will only get better over time. As its hardware requirements are relatively low, this technology can reach and help large numbers of patients around the world.”

Brief about the investors

LUMO Labs provides opportunities to impact-driven software and smart hardware startups. The current LUMO Fund II is a multi-stage capital fund with an impact focus (pre-seed up to and including series A). To assist its portfolio firms in achieving financial success as well as social traction and impact, it offers a two-year venture-building programme.

Startups that support at least one of the three Sustainable Development Goals of the UN—Sustainable Cities & Communities, Good Health & Well-Being, and Quality Education—are funded by LUMO Labs. 

Its investment priorities include blockchain, the Internet of Things, robotics and drones, virtual reality, and augmented reality. The firm also focuses on artificial intelligence and data.

The NOM is the investment and development agency for the Northern Netherlands, which includes Groningen, Friesland, and Drenthe, the three northernmost provinces that together make up the TopDutch economic zone. 

The TopDutch area offers digital and green solutions to the world’s problems.

NOM promotes the growth of businesses and jobs in the Northern Netherlands. It gives advice on site selection, encourages investment in the Northern Netherlands, and launches programmes that improve the competitiveness of local businesses. It also offers risk-bearing finance.

 - Partner content -
How to succesfully outsource…
How to succesfully outsource…
...your recruitment or product development with our curated community partners!
...your recruitment or product development with our curated community partners! Show Less
Read more
Tags: fundingnews
Share2Tweet8SendShare12

Partner with us | Download Media Kit

Thank you for visiting Silicon Canals! If you want to partner with us, look at our options.

Featured | Tech Events

Current Month

september, 2023

Silicon Canals | Jobs

Breaking news from Amsterdam | Partner

Chemical Utopia: How Amsterdam Chemistry Network’s ChemAI aims to upend Dutch Chemistry

Amsterdam’s Truvity launches Truvity Platform to revolutionise digital identity verification technology

Amsterdam’s Bynder acquires EMRAYS to enhance AI search solutions for Digital Asset Management

Partner content | Work with us

[Exclusive] Amsterdam’s YourKitchen gets acquired by The Kitchen Dojo and Trias Real Estate: Know more

Meet Samaa Mohammad, an AI ethicist solving diversity problem with Techleap.nl’s DLiT Community

Founders on Bootstrapping: How Swapkaart is disrupting the business cards game being bootstrapped

  • About Silicon Canals
  • Partner with Silicon Canals
  • Impressum
  • Contact us
  • Sign up for our newsletter!
  • Disclaimer
  • Privacy Policy
  • Cookie Policy (UK)
  • Cookie Policy (EU)
  • Terms & Conditions Silicon Canals

Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos

No Result
View All Result
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Community partners
    • Amsterdam
    • Rise by Techleap.nl
    • EOR handbook by Atlas HXM
    • Guest Contributions
    • Business Wire
    • Sign up for our newsletter!
  • Global Jobs
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Contribute your content
    • Team
    • About us
  • Partner with us

Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos

X
X